Quantinuum publicly files Form S-1 for Nasdaq IPO under ticker QNT, FY2025 net revenue $30.9M and $677M cash; J.P. Morgan and Morgan Stanley joint lead bookrunners
On 2026-05-08 Honeywell announced that Quantinuum Inc. publicly filed a Form S-1 registration statement with the SEC for a proposed initial public offering of Class A common stock. Per the SEC EDGAR filing (accession 0001628280-26-032836, file number 333-295701, CIK 0002110105, 22 MB filing comprising 16 documents), Quantinuum intends to list on the Nasdaq Global Market under ticker symbol QNT. The cover page is marked SUBJECT TO COMPLETION DATED MAY 8, 2026, and the number of shares to be offered and the price range have not yet been determined. J.P. Morgan and Morgan Stanley are joint lead active book-running managers; Jefferies and Evercore ISI are also acting as active book-running managers. The S-1 discloses audited annual financial highlights of FY2024 net revenue $23.0M and net loss $144.1M, FY2025 net revenue $30.9M (+34% YoY) and net loss $192.6M, and a Q1 2026 stub-period net revenue of $5.2M with net loss $136.6M and bookings of $1.3M (versus Q1 2025 bookings of $1.9M). Cash and equivalents at 2026-03-31 are $677.0M. The public S-1 follows the confidential draft submission disclosed 2026-04-22 (event 2026-04-23-honeywell-q1-2026-quantinuum-ipo-confirmation-deconsolidation, score 7) and the original confidential filing date of 2026-02-17. The filing converts the most-watched open thread in /meta/state.json (Quantinuum IPO pending) from a confidential-paperwork stage to a live, publicly-readable registration statement that the market and prospective investors can now price.
Score 8 — this is the public S-1 filing for the largest pure-play quantum revenue name, meaningfully advancing the §8.2 anchor row 'Concrete advance with near-term consequence — standards, capital, architecture, or capability' (band 8). The filing crosses a discrete regulatory threshold: confidential-S-1 paperwork (since 2026-02-17) is private and price-discovery-free; a public S-1 is the predicate to a roadshow, pricing range disclosure, and listing. Named bookrunners (J.P. Morgan, Morgan Stanley, Jefferies, Evercore ISI) and a chosen ticker (QNT) and exchange tier (Nasdaq Global Market) commit the issuer to a specific listing path. Held below score 9 because pricing range, share count, and use of proceeds are explicitly TBD on the cover page; the priced-listing event remains the score-9 trigger per /meta/state.json open_threads anchor. Held below score 10 because Quantinuum is not yet trading. Per CLAUDE.md close-call-rounds-down discipline, 8 is the defensible band: the public S-1 is a major capital event whose financial disclosures (FY2025 revenue $30.9M, $677M cash, $192.6M net loss) reset the public-market revenue and cash-runway comparables for the listed-quantum universe ahead of Quantinuum's actual debut. Source confidence high (SEC EDGAR filing, Honeywell IR press release, Quantinuum press release, Stocktitan, TQI); interpretation confidence high.
Resolves the priority-1 open thread in state.open_threads from 'confidential paperwork submitted' to 'public S-1 filed' and pre-positions the next milestone (priced offering, expected to be the score-9 trigger). Establishes Quantinuum's audited FY2025 revenue base ($30.9M) as the new pure-play quantum revenue benchmark, immediately comparable to IonQ's Q1 2026 record print ($64.7M, +755% YoY, full-year guide $260-270M reaffirmed 2026-05-06) — IonQ now visibly outpaces Quantinuum on revenue trajectory at a roughly 8-9x annualized run-rate, narrowing the long-running 'who is the largest pure-play quantum company by revenue' question that has framed Honeywell's quantum-strategy commentary since the 2021 Cambridge Quantum merger. Confirms Honeywell's Q2 2026 Quantinuum deconsolidation guidance (per 2026-04-23 event) by removing the last procedural barrier to deconsolidation. Cash runway analysis becomes possible for the first time: $677M cash at 2026-03-31 against an annualized FY2025 net-loss run-rate of $192.6M implies roughly 3.5 years of operating runway pre-IPO, before any new IPO proceeds. Accelerates competitive comparable-pricing analysis at the listed-quantum cohort (IonQ, Rigetti, D-Wave, QUBT, Arqit, SealSQ, Xanadu, plus Horizon Quantum) as Quantinuum's revenue and unit-economics now anchor a new high-quality data point. Watch for: (a) the SEC's first-round comment-letter response timeline, typically 30-60 days from public filing; (b) any updated S-1/A with disclosed price range and share count, the event that locks in the score-9 roadshow milestone; (c) listing-eligibility status given Nasdaq Global Market listing standards (Quantinuum's pre-IPO equity value is well above the $80M float minimum and the $11M aggregate market value of publicly held shares, but the audited two-year-loss profile means the IPO will price under the 'Equity Standard' or 'Market Value of Listed Securities Standard'); (d) any disclosed Honeywell post-IPO ownership percentage, which the press release says will be majority retained but the cover-page redaction means is not yet quantified; (e) lock-up terms in the final pricing prospectus; (f) Quantinuum's own roadshow-disclosed customer revenue concentration and named-pilot list, which the public S-1 references generically as 'pharmaceuticals, material science, financial services, and government and industrial markets' but is expected to specify in the final prospectus. The dilution-overhang thread (anchor 2026-05-04-xanadu-294m-share-resale-registration) gains a counterweight in the QNT IPO float-creation event, which would add primary-issued public shares to the listed-quantum universe rather than secondary resale of locked-up shares.